On Friday, Century Therapeutics Inc (NASDAQ: IPSC) was -4.79% drop from the session before settling in for the closing price of $1.46. A 52-week range for IPSC has been $1.28 – $5.51.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -14.25% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 23.46%. With a float of $32.26 million, this company’s outstanding shares have now reached $60.34 million.
In an organization with 165 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -488.98%, operating margin of -6517.58%, and the pretax margin is -6446.67%.
Century Therapeutics Inc (IPSC) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Century Therapeutics Inc stocks. The insider ownership of Century Therapeutics Inc is 61.92%, while institutional ownership is 28.87%. The most recent insider transaction that took place on Sep 12 ’24, was worth 7,657. In this transaction Director of this company bought 5,000 shares at a rate of $1.53, taking the stock ownership to the 5,000 shares. Before that another transaction happened on Aug 05 ’24, when Company’s Chief Operations Officer sold 1,073 for $1.83, making the entire transaction worth $1,960. This insider now owns 136,163 shares in total.
Century Therapeutics Inc (IPSC) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 23.46% per share during the next fiscal year.
Century Therapeutics Inc (NASDAQ: IPSC) Trading Performance Indicators
You can see what Century Therapeutics Inc (IPSC) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 10.62. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 57.73.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.04, a number that is poised to hit -0.45 in the next quarter and is forecasted to reach -1.86 in one year’s time.
Technical Analysis of Century Therapeutics Inc (IPSC)
Let’s dig in a bit further. During the last 5-days, its volume was 0.29 million. That was better than the volume of 0.25 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 28.74%. Additionally, its Average True Range was 0.12.
During the past 100 days, Century Therapeutics Inc’s (IPSC) raw stochastic average was set at 2.82%, which indicates a significant decrease from 18.75% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.48% in the past 14 days, which was lower than the 88.69% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5965, while its 200-day Moving Average is $2.9344. However, in the short run, Century Therapeutics Inc’s stock first resistance to watch stands at $1.4567. Second resistance stands at $1.5233. The third major resistance level sits at $1.5867. If the price goes on to break the first support level at $1.3267, it is likely to go to the next support level at $1.2633. Assuming the price breaks the second support level, the third support level stands at $1.1967.
Century Therapeutics Inc (NASDAQ: IPSC) Key Stats
There are 84,501K outstanding shares of the company, which has a market capitalization of 117.76 million. As of now, sales total 2,240 K while income totals -136,670 K. Its latest quarter income was 770 K while its last quarter net income were -31,210 K.
